Discontinue use if myopathy is suspected based on muscle symptoms or confirmed by creatine phosphokinase level >10x ULN; cholelithiasis & gall bladder diseases is suspected in a patient receiving treatment concomitantly w/ fenofibrate. Increased risk of rhabdomyolysis. Consecutive transaminase elevations (≥3x ULN). Perform LFTs at initiation of therapy. Monitor ciclosporin conc, & INR in patient receiving treatment concomitantly w/ ciclosporin, & warfarin, another coumarin anticoagulant, or fluindione, respectively. Galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Not recommended in patients w/ moderate or severe hepatic impairment. Pregnancy. Not to be used during lactation. Childn <6 yr.
Sign Out
